Renaissance Technologies
TAK icon

Renaissance Technologies’s Takeda Pharmaceutical TAK Stock Holding History

Renaissance Technologies’s Portfolio TAK Stock Details TAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$41.2M Sell
2,568,000
-421,100
-14% -$6.97M 0.06% 406
2026
Q1 		$55.4M Buy
2,989,100
+370,800
+14% +$6.51M 0.09% 291
2025
Q4 		$40.8M Sell
2,618,300
-1,246,300
-32% -$17.8M 0.06% 346
2025
Q3 		$56.6M Buy
3,864,600
+565,400
+17% +$8.4M 0.07% 307
2025
Q2 		$51M Buy
3,299,200
+141,500
+4% +$2.09M 0.07% 335
2025
Q1 		$47M Buy
3,157,700
+78,300
+3% +$1.1M 0.07% 344
2024
Q4 		$40.8M Sell
3,079,400
-139,400
-4% -$1.91M 0.06% 388
2024
Q3 		$45.8M Buy
3,218,800
+264,000
+9% +$3.74M 0.07% 344
2024
Q2 		$38.2M Sell
2,954,800
-163,400
-5% -$2.16M 0.06% 367
2024
Q1 		$43.3M Sell
3,118,200
-209,200
-6% -$3.04M 0.07% 346
2023
Q4 		$47.5M Buy
3,327,400
+96,500
+3% +$1.37M 0.07% 313
2023
Q3 		$50M Sell
3,230,900
-419,100
-11% -$6.49M 0.09% 270
2023
Q2 		$57.3M Buy
3,650,000
+676,600
+23% +$11.1M 0.08% 279
2023
Q1 		$49M Buy
2,973,400
+109,000
+4% +$1.74M 0.07% 355
2022
Q4 		$44.7M Buy
2,864,400
+15,300
+0.5% +$214K 0.06% 373
2022
Q3 		$37M Buy
2,849,100
+20,800
+0.7% +$289K 0.05% 417
2022
Q2 		$39.7M Buy
2,828,300
+835,100
+42% +$11.9M 0.05% 433
2022
Q1 		$28.5M Buy
1,993,200
+274,400
+16% +$4.03M 0.03% 563
2021
Q4 		$23.4M Sell
1,718,800
-438,100
-20% -$6.15M 0.03% 633
2021
Q3 		$35.3M Sell
2,156,900
-140,100
-6% -$2.35M 0.05% 415
2021
Q2 		$38.7M Sell
2,297,000
-1,137,600
-33% -$19.4M 0.05% 419
2021
Q1 		$62.7M Sell
3,434,600
-2,144,100
-38% -$38.6M 0.08% 278
2020
Q4 		$102M Sell
5,578,700
-158,007
-3% -$2.77M 0.11% 185
2020
Q3 		$102M Buy
5,736,707
+129,007
+2% +$2.35M 0.1% 201
2020
Q2 		$101M Buy
5,607,700
+1,844,300
+49% +$33.1M 0.09% 244
2020
Q1 		$57.1M Buy
3,763,400
+1,755,211
+87% +$31.8M 0.06% 351
2019
Q4 		$39.6M Buy
2,008,189
+303,789
+18% +$5.81M 0.03% 637
2019
Q3 		$29.3M Buy
1,704,400
+930,600
+120% +$16.1M 0.02% 749
2019
Q2 		$13.7M Buy
+773,800
New +$14.1M 0.01% 1198

Other funds holding TAK

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Renaissance Technologies's TAK Position: Q2 2026 in Review

Renaissance Technologies reduced its Takeda Pharmaceutical (TAK) stake by 14% in Q2 2026, selling an estimated $6.97M and leaving 2,568,000 shares worth $41.2M. The position accounts for 0.06% of the portfolio, ranked #406.

Renaissance Technologies first reported a position in TAK in Q2 2019 and has held it in 29 quarters since. The position peaked at $102M in Q3 2020. 378 funds tracked by Wall St. Rank hold TAK as of Q2 2026.

  • Renaissance Technologies held 2,568,000 shares of Takeda Pharmaceutical worth $41.2M as of Q2 2026.
  • Renaissance Technologies sold 421,100 Takeda Pharmaceutical shares in Q2 2026, an estimated $6.97M.
  • Takeda Pharmaceutical made up 0.06% of Renaissance Technologies's portfolio in Q2 2026, its #406 holding.
  • Renaissance Technologies first reported a position in Takeda Pharmaceutical in Q2 2019 and has held it in 29 quarters since.
  • Renaissance Technologies's Takeda Pharmaceutical position peaked at $102M in Q3 2020.
  • 378 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q2 2026.

Based on Renaissance Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.